Press Release: Leidos, Inc. Commences Tender Offer for Any and All 3.625% Senior Notes Due 2025

Dow Jones
02-13
      procurement rules and regulations; 
 
   -- governmental reviews, audits and investigations of our company; 
 
   -- our ability to effectively compete and win contracts with the U.S. 
      government and other customers; 
 
   -- our ability to respond rapidly to emerging technology trends, including 
      the use of artificial intelligence; 
 
   -- our reliance on information technology spending by hospitals/healthcare 
      organizations; 
 
   -- our reliance on infrastructure investments by industrial and natural 
      resources organizations; 
 
   -- energy efficiency and alternative energy sourcing investments; 
 
   -- investments by U.S. government and commercial organizations in 
      environmental impact and remediation projects; 
 
   -- the effects of an epidemic, pandemic or similar outbreak may have on our 
      business, financial position, results of operations and/or cash flows; 
 
   -- our ability to attract, train and retain skilled employees, including our 
      management team, and to obtain security clearances for our employees; 
 
   -- our ability to accurately estimate costs, including cost increases due to 
      inflation, associated with our firm-fixed-price ("FFP") contracts and 
      other contracts; 
 
   -- resolution of legal and other disputes with our customers and others or 
      legal or regulatory compliance issues; 
 
   -- cybersecurity, data security or other security threats, system failures 
      or other disruptions of our business; 
 
   -- our compliance with international, federal, state and local laws and 
      regulations regarding privacy, data security, protection, storage, 
      retention, transfer, disposal and other processing, technology protection 
      and personal information; 
 
   -- the damage and disruption to our business resulting from natural 
      disasters and the effects of climate change; 
 
   -- our ability to effectively acquire businesses and make investments; 
 
   -- our ability to maintain relationships with prime contractors, 
      subcontractors and joint venture partners; 
 
   -- our ability to manage performance and other risks related to customer 
      contracts; 
 
   -- the failure of our inspection or detection systems to detect threats; 
 
   -- the adequacy of our insurance programs, customer indemnifications or 
      other liability protections designed to protect us from significant 
      product or other liability claims, including cybersecurity attacks; 
 
   -- our ability to manage risks associated with our international business; 
 
   -- our ability to comply with the U.S. Foreign Corrupt Practices Act, the 
      U.K. Bribery Act of 2010 and similar worldwide anti-corruption and 
      anti-bribery laws and regulations; 
 
   -- our ability to protect our intellectual property and other proprietary 
      rights by third parties of infringement, misappropriation or other 
      violations by us of their intellectual property rights; 
 
   -- our ability to prevail in litigation brought by third parties of 
      infringement, misappropriation or other violations by us of their 
      intellectual property rights; 
 
   -- our ability to declare or increase future dividends based on our earnings, 
      financial condition, capital requirements and other factors, including 
      compliance with applicable law and our agreements; 
 
   -- our ability to grow our commercial health and infrastructure businesses, 
      which could be negatively affected by budgetary constraints faced by 
      hospitals and by developers of energy and infrastructure projects; 
 
   -- our ability to successfully integrate acquired businesses; and 
 
   -- our ability to execute our business plan and long-term management 
      initiatives effectively and to overcome these and other known and unknown 
      risks that we face. 

These are only some of the factors that may affect the forward-looking statements contained in this release. For further information concerning risks and uncertainties associated with our business, please refer to the filings we make from time to time with the U.S. Securities and Exchange Commission ("SEC"), including the "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Legal Proceedings" sections of our latest Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

All information in this release is as of February 13, 2025. We do not undertake any obligation to update or revise any of the forward-looking statements to reflect events, circumstances, changes in expectations, or the occurrence of unanticipated events after the date of those statements or to conform these statements to actual results.

CONTACTS:

Investor Relations:

Stuart Davis

571.526.6124

ir@leidos.com

Media Relations:

Victor Melara

(703) 431-4612

victor.a.melara@leidos.com

View original content:https://www.prnewswire.com/news-releases/leidos-inc-commences-tender-offer-for-any-and-all-3-625-senior-notes-due-2025--302376071.html

SOURCE Leidos

 

(END) Dow Jones Newswires

February 13, 2025 08:43 ET (13:43 GMT)

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10